General Surgery
Final Professional MBBS — General Surgery. Explanation-first answers that teach the reasoning behind every fact, with classifications, comparison tables, drug doses, clinical pearls and key-point recaps from Bailey & Love and SRB's Manual.
THE CONCEPT & RISK FACTORS
Breast carcinoma is the commonest cancer in women, and understanding it begins with the idea that most cancers are oestrogen-driven — anything that increases a woman's lifetime exposure to oestrogen raises her risk. This explains the classic risk factors: early menarche and late menopause (a longer reproductive span), nulliparity or a first pregnancy after 30 (pregnancy is protective), obesity (fat converts androgens to oestrogen after menopause), and prolonged hormone use. Added to these are increasing age, a family history, and the inherited BRCA1/BRCA2 gene mutations, which confer a very high lifetime risk.
PATHOLOGY
Most cancers arise from the ducts. The key distinction is between carcinoma in situ (malignant cells confined by the basement membrane — DCIS, a premalignant/non-invasive stage) and invasive carcinoma (cells breached the basement membrane and can metastasise). The commonest is invasive ductal carcinoma (no special type), followed by invasive lobular carcinoma. Every tumour is assessed for three receptors that guide treatment: oestrogen (ER) and progesterone (PR) receptors, and HER2.
CLINICAL FEATURES
The commonest presentation is a painless, hard, irregular, fixed lump, usually in the upper outer quadrant. Signs of local advancement teach the anatomy of spread: skin tethering or dimpling and nipple retraction (infiltration of the ligaments of Cooper and ducts), peau d'orange (skin oedema from dermal lymphatic blockage), fixation to the chest wall, and palpable axillary nodes. Distant spread is to bone, lung, liver and brain.
TRIPLE ASSESSMENT & STAGING
Any breast lump is worked up by triple assessment — clinical examination, imaging (mammography ± ultrasound), and needle biopsy (core biopsy) — which together give a near-certain diagnosis. Staging uses the TNM system (tumour size, nodal involvement, metastasis), and the axillary nodes are the single most important prognostic factor.
MANAGEMENT — A MULTIMODAL APPROACH
Treatment combines surgery, radiotherapy and systemic therapy, tailored to stage and receptor status:
- Surgery — either breast-conserving surgery (wide local excision) for smaller tumours (always followed by radiotherapy), or mastectomy for larger/multifocal tumours. The axilla is staged by sentinel lymph node biopsy; if involved, an axillary clearance is done.
- Radiotherapy — after conservation surgery and after mastectomy for high-risk disease, to reduce local recurrence.
- Endocrine therapy for ER-positive tumours — tamoxifen (premenopausal) or an aromatase inhibitor (postmenopausal), exploiting the oestrogen dependence.
- Chemotherapy for higher-risk/node-positive disease, and trastuzumab (Herceptin) for HER2-positive tumours.
ROUTES OF SPREAD
Understanding how breast cancer spreads explains both its staging and its clinical signs. Local spread invades the skin (tethering, ulceration, peau d'orange) and the pectoral muscle/chest wall. Lymphatic spread — the main early route — is chiefly to the axillary nodes (and less commonly the internal mammary and supraclavicular nodes), which is why axillary status is so central to prognosis. Blood-borne spread seeds the classic sites — bone (the commonest, causing pain and pathological fractures), lung, liver and brain. This is why staging investigations in advanced disease target these organs.
PROGNOSTIC FACTORS
Prognosis is estimated from several factors combined (e.g. in the Nottingham Prognostic Index): lymph node status (the most powerful), tumour size, and histological grade, together with receptor status. A small, low-grade, node-negative, ER-positive tumour carries an excellent outlook, whereas a large, high-grade, node-positive or triple-negative tumour does far worse — and it is this profile, not the diagnosis of 'cancer' alone, that guides how aggressively the patient is treated.
SCREENING
Because early, impalpable cancers (especially DCIS, detected as microcalcification) are far more curable, population mammographic screening is offered to women in the target age band (typically ~50–70 years, three-yearly in many programmes). High-risk women (strong family history, BRCA carriers) are screened earlier and with MRI. The principle is that detecting cancer before it is palpable improves survival.
LOCALLY ADVANCED & METASTATIC DISEASE
Not all breast cancer is operable at presentation. Locally advanced disease (large fixed tumours, skin/chest-wall involvement, matted nodes, or inflammatory cancer) is usually treated first with neoadjuvant chemotherapy to shrink the tumour and make surgery possible, followed by surgery and radiotherapy. Metastatic disease is not curable but is very treatable, and the aim shifts to controlling the disease and maintaining quality of life with endocrine therapy, chemotherapy, targeted agents (e.g. trastuzumab), and bone-directed treatment (bisphosphonates) for skeletal metastases. This palliative-but-active philosophy means many women live for years with controlled metastatic disease.
BREAST RECONSTRUCTION & THE MDT
Modern breast cancer care is delivered by a multidisciplinary team (surgeon, oncologist, radiologist, pathologist, specialist nurse) that individualises treatment to the tumour biology and the patient's wishes. Reconstruction — immediate or delayed, using an implant or the patient's own tissue (latissimus dorsi or DIEP flap) — is an integral part of mastectomy care, restoring body image. Psychological support, genetic counselling for BRCA carriers, and clear discussion of the risks and benefits of each option are all part of a comprehensive, patient-centred plan rather than surgery in isolation.
💊KEY DOSES / NUMBERS (viva)- Tamoxifen 20 mg daily for ER-positive disease (usually 5–10 years).
- Sentinel node biopsy is the standard for staging a clinically negative axilla.
- Axillary nodal status = the single most important prognostic factor.
💡CLINICAL PEARL: The receptors dictate therapy, so they must always be checked: an ER-positive tumour gets endocrine therapy, a HER2-positive tumour gets trastuzumab, and a 'triple-negative' tumour (ER/PR/HER2 all negative) has neither target and relies on chemotherapy — carrying a worse prognosis.🔑KEY POINTS TO REMEMBER- Mostly oestrogen-driven; risk rises with lifetime oestrogen exposure (early menarche/late menopause, nulliparity), age, family history, BRCA1/2.
- Pathology: DCIS (in situ, premalignant) vs invasive (ductal commonest); always test ER, PR, HER2.
- Painless hard irregular fixed lump (upper outer quadrant); skin tethering, nipple retraction, peau d'orange, axillary nodes; spreads to bone/lung/liver/brain.
- Diagnose by triple assessment; stage by TNM; axillary nodes = most important prognostic factor.
- Multimodal: conservation+radiotherapy or mastectomy, sentinel node biopsy; tamoxifen/aromatase inhibitor (ER+), trastuzumab (HER2+), chemotherapy (high-risk/triple-negative).
📚SOURCES: Bailey & Love's Short Practice of Surgery; SRB's Manual of Surgery.THE CONCEPT — ANDI
Most breast lumps and symptoms are benign, and the modern way to understand them is the concept of ANDI — Aberrations of Normal Development and Involution. The insight is that the breast is not a static organ: across a woman's life it develops, cycles monthly, and involutes, and most 'benign breast disease' is simply a minor aberration of these normal processes rather than true disease. This reframing explains why these conditions are so common, age-related, and usually need reassurance rather than aggressive treatment.
FIBROADENOMA — AN ABERRATION OF DEVELOPMENT
A fibroadenoma arises from a single lobule that overgrows, and occurs in young women (15–30). It is the classic 'breast mouse' — a smooth, firm, highly mobile, painless lump. It is benign with negligible malignant potential; after triple assessment confirms it, small ones may simply be observed, with excision for larger, growing or symptomatic ones.
FIBROCYSTIC CHANGE — AN ABERRATION OF CYCLING
Fibrocystic change reflects an exaggerated response to the monthly hormonal cycle, and occurs in the 30–50 age group. It causes cyclical breast pain (mastalgia), lumpiness and nodularity that worsen premenstrually. It is benign; management is reassurance, a supportive bra, and simple analgesia, with cysts aspirated if symptomatic.
BREAST CYSTS — AN ABERRATION OF INVOLUTION
Cysts are common in the perimenopausal years (35–50) as lobules involute and their ducts become distended with fluid. They present as a smooth, sometimes tender, discrete lump. On ultrasound they are clearly fluid-filled; a simple cyst is aspirated and, if the fluid is not bloodstained and the lump disappears completely, needs no further action. Bloodstained fluid or a residual lump requires biopsy to exclude malignancy.
OTHER BENIGN CONDITIONS
- Duct ectasia — dilated, shortened ducts in older women, causing thick cheesy nipple discharge and nipple retraction (a benign mimic of cancer).
- Fat necrosis — a firm lump after trauma that can mimic cancer and needs triple assessment to distinguish.
- Galactocele — a milk-filled cyst during lactation.
- Duct papilloma — a benign wart-like growth in a duct, the commonest cause of blood-stained nipple discharge.
💡CLINICAL PEARL: The golden rule with any 'benign' lump is that the diagnosis is only safe after triple assessment. Reassurance without proper work-up is dangerous, because a cancer can occasionally masquerade as a benign lump — so the benign label is earned by examination, imaging and biopsy, not by clinical impression alone.MASTALGIA (BREAST PAIN)
Breast pain is one of the commonest reasons women present, and separating it into types guides management. Cyclical mastalgia (linked to the menstrual cycle, bilateral, part of fibrocystic change) is the commonest and responds to reassurance, a supportive bra and simple analgesia. Non-cyclical mastalgia may arise from the breast (e.g. duct ectasia) or from the chest wall (costochondritis — Tietze's syndrome). The reassuring message is that breast pain alone is rarely a symptom of cancer, so the main task is to exclude a lump and reassure.
FAT NECROSIS & GALACTOCELE
Two specific benign lumps are worth knowing. Fat necrosis follows trauma (often forgotten by the patient) and produces a firm, sometimes tethered lump that can mimic carcinoma clinically and on mammography — so it requires triple assessment to be sure. A galactocele is a milk-filled cyst occurring during or after lactation, presenting as a smooth cystic lump that resolves on aspiration.
THE PRINCIPLE OF SAFE REASSURANCE
Across all benign conditions the governing rule is the same: a lump or symptom is labelled benign only after triple assessment has excluded malignancy, after which the patient can be confidently reassured and spared unnecessary surgery. Over-treating benign disease and under-investigating a 'benign-feeling' cancer are the two errors this discipline prevents.
CLINICAL APPROACH TO A BENIGN LUMP
Bringing the conditions together, the practical approach to a woman with a breast lump is: take a focused history (age, duration, cyclical change, pain, discharge, risk factors), examine both breasts and the regional nodes, and arrange triple assessment matched to age (ultrasound if young, mammography added if older). The age of the patient is itself a strong clue — a mobile lump at 20 is most likely a fibroadenoma, cyclical nodularity at 40 is fibrocystic change, a smooth lump at 45 is often a cyst, and a hard fixed lump at 60 must be treated as cancer until proven otherwise.
A PRACTICAL DIAGNOSTIC FRAMEWORK
In the clinic the age of the patient plus the character of the lump usually predicts the diagnosis before investigation: a highly mobile firm lump at 20 suggests a fibroadenoma; cyclical nodularity at 40 suggests fibrocystic change; a smooth discrete lump at 45 suggests a cyst; and a hard, irregular, fixed lump at 60 must be treated as cancer. This framework does not replace triple assessment — it directs it — and it embodies the safe principle that the 'benign' label is only ever confirmed after imaging and needle biopsy, never on clinical impression alone.
🔑KEY POINTS TO REMEMBER- ANDI = Aberrations of Normal Development and Involution — most benign breast disease is a minor aberration of normal breast processes.
- Fibroadenoma (young, 15–30): smooth, firm, very mobile painless 'breast mouse'; benign.
- Fibrocystic change (30–50): cyclical mastalgia, lumpiness, nodularity; reassurance + supportive bra + analgesia.
- Cysts (perimenopausal, 35–50): fluid-filled; aspirate — biopsy if bloodstained fluid or residual lump.
- Also duct ectasia, fat necrosis, galactocele, duct papilloma (commonest cause of bloody discharge); confirm 'benign' only after triple assessment.
📚SOURCES: Bailey & Love's Short Practice of Surgery.THE CONCEPT — WHY THREE, NOT ONE
Triple assessment is the cornerstone of breast diagnosis: every discrete breast lump or suspicious symptom is evaluated by three independent methods — clinical assessment, imaging, and pathology (needle biopsy). The logic is that no single test is perfect — each has false negatives — but when all three agree, the diagnosis is near-certain (accuracy > 99%). Combining them means a cancer is very unlikely to be missed and a benign lump can be confidently reassured, ideally in a single 'one-stop' clinic visit.
1. CLINICAL ASSESSMENT
A careful history notes the lump's duration and change, relation to the menstrual cycle, pain, nipple discharge, and risk factors. Examination inspects for asymmetry, skin changes (dimpling, peau d'orange), and nipple retraction, then palpates the lump (size, consistency, mobility, fixation) and the axillary and supraclavicular nodes. Findings are scored (e.g. P1 normal to P5 malignant). Clinical assessment alone can be misleading, which is exactly why the other two components exist.
2. IMAGING
Imaging is chosen by age because breast density differs:
- Mammography — the imaging of choice in women over about 35, whose breasts are less dense. It detects masses and, importantly, microcalcifications — a key sign of DCIS not palpable clinically.
- Ultrasound — preferred in younger women (< 35) with dense breasts, and used in all ages to characterise a lump as solid or cystic and to guide biopsy.
- MRI — reserved for specific situations (e.g. screening BRCA carriers, assessing lobular cancer or implants).
Imaging is also scored (M1–M5 / U1–U5).
3. PATHOLOGY (NEEDLE BIOPSY)
Tissue diagnosis is obtained by needle:
- Core needle biopsy — the preferred method, because it takes a core of tissue that shows the histological architecture, distinguishes invasive from in-situ disease, and allows receptor (ER/PR/HER2) testing — all essential for planning treatment.
- Fine needle aspiration cytology (FNAC) — quicker but only gives cells (cytology, C1–C5), and cannot tell invasive from in-situ; now largely superseded by core biopsy.
INTERPRETING THE RESULTS
The three arms are considered together. Concordant results (all benign, or all malignant) give a confident diagnosis. Discordance — for example a clinically suspicious lump with a benign biopsy — is a red flag that must never be ignored; it prompts repeat biopsy or diagnostic excision, because it may reflect a sampling error missing a cancer.
💡CLINICAL PEARL: The most important safety principle is that discordance overrides reassurance. If the clinical or imaging suspicion is high but the biopsy is benign, you do not accept the benign result — you re-biopsy or excise. Trusting a single reassuring test in the face of contrary evidence is how cancers are missed.THE ONE-STOP CLINIC
Triple assessment is ideally delivered in a 'one-stop' breast clinic, where clinical examination, imaging and needle biopsy are all performed at a single visit, with results discussed the same day where possible. This design reflects the whole philosophy of the approach: rapid, combined assessment minimises the anxiety of waiting and the risk of losing patients to follow-up, and reaches a reliable diagnosis quickly.
SCORING SYSTEMS
Each arm is given a numerical score so the team can integrate them objectively: clinical P1–P5, imaging M1–M5 (mammography) and U1–U5 (ultrasound), and pathology B1–B5 (core biopsy) or C1–C5 (cytology) — in each case 1 being normal/benign and 5 being malignant. Concordant high scores confirm cancer and allow definitive treatment to be planned; concordant low scores allow discharge.
LIMITATIONS & THE ROLE OF EXCISION BIOPSY
No test is infallible: mammography is less sensitive in the dense breasts of younger women, and needle biopsy can miss a small or heterogeneous lesion (sampling error). When the arms are discordant, or a lesion is scored as indeterminate/atypical (e.g. B3), a diagnostic excision biopsy (often after image-guided wire localisation for impalpable lesions) is performed to obtain the definitive answer.
IMPALPABLE LESIONS
Screening detects many impalpable abnormalities (a cluster of microcalcification, or a small mass seen only on imaging). These cannot be felt, so they are sampled under image guidance — stereotactic or ultrasound-guided core biopsy — and, if excision is needed, localised first with a guidewire or radioactive/magnetic seed placed by the radiologist so the surgeon can remove the correct area, with a specimen X-ray confirming the lesion has been excised. This is how modern practice deals with cancers found before they are ever palpable.
SPECIAL CLINICAL SCENARIOS
Triple assessment adapts to particular situations. In pregnancy and lactation, ultrasound is the first-line image (avoiding radiation) and any suspicious lump is still biopsied, because pregnancy-associated cancers are easily missed. In the screening-detected impalpable lesion, the whole process is image-led — stereotactic core biopsy, and wire or seed localisation for excision. In a young woman with a classic fibroadenoma, clinical assessment plus ultrasound and core biopsy may permit safe conservative management. The method flexes to the context while never abandoning its three-arm principle.
🔑KEY POINTS TO REMEMBER- Triple assessment = clinical + imaging + needle biopsy for every discrete lump; combined accuracy >99%.
- Clinical: history + examination of lump and regional nodes (scored P1–P5).
- Imaging: mammography if >35 (detects microcalcification/DCIS), ultrasound if <35 or to characterise solid/cystic; MRI selectively.
- Pathology: core biopsy preferred (shows architecture, invasive vs in-situ, ER/PR/HER2) over FNAC.
- Concordant results confirm the diagnosis; discordance mandates re-biopsy/excision — never ignore it.
📚SOURCES: Bailey & Love's Short Practice of Surgery; SRB's Manual of Surgery.THE CONCEPT
A breast abscess is a localised collection of pus in the breast, almost always the end-result of mastitis (inflammation/infection of breast tissue) that has not resolved. Understanding the two settings in which it occurs — lactational and non-lactational — explains the different organisms, sites and management, and the general surgical principle that pus must be drained applies throughout.
LACTATIONAL (PUERPERAL) MASTITIS & ABSCESS
This is the common form, occurring in breastfeeding mothers, typically a few weeks postpartum. The mechanism is milk stasis plus a cracked nipple that lets skin bacteria — usually Staphylococcus aureus — enter and infect stagnant milk, which is an ideal culture medium. It presents with a painful, red, hot, swollen, wedge-shaped area and fever. If a fluctuant collection develops, an abscess has formed.
NON-LACTATIONAL ABSCESS
This occurs outside lactation and is strongly associated with smoking and duct ectasia/periductal mastitis. It tends to be periareolar (around the nipple) and is more prone to recur and to form a mammary duct fistula. The organisms are often mixed, including anaerobes, so antibiotic choice differs.
MANAGEMENT
Management follows the stage:
- Cellulitis/mastitis (no pus yet) — antibiotics (flucloxacillin for lactational; co-amoxiclav/metronidazole cover for non-lactational anaerobes), analgesia, and — importantly in lactational mastitis — continued breastfeeding or expression to relieve the milk stasis that drives it.
- Established abscess (fluctuant/pus) — antibiotics alone will not cure a collection, so it must be drained. The modern first-line is ultrasound-guided needle aspiration (repeated as needed), reserving incision and drainage for large or multiloculated abscesses.
- A biopsy of the abscess wall is taken in non-lactational or atypical cases to exclude an underlying inflammatory carcinoma.
💡CLINICAL PEARL: Two safety points: never forget that an inflammatory breast cancer can masquerade as a 'mastitis' or 'abscess' that fails to settle — so any non-resolving inflammatory breast lesion needs imaging and biopsy. And in a smoker with recurrent periareolar abscesses, stopping smoking is essential, as it is central to the underlying periductal disease.PATHOGENESIS OF THE LACTATIONAL ABSCESS
The sequence in a breastfeeding mother is worth spelling out because it guides prevention. Milk stasis (from poor latch, missed feeds or blocked ducts) provides a stagnant, nutrient-rich medium; a cracked or fissured nipple provides the portal of entry for skin Staphylococcus aureus; the organism multiplies, causing cellulitic mastitis, which — if not relieved by continued drainage of milk and antibiotics — progresses to a walled-off collection of pus, the abscess. Good latch, frequent feeding and nipple care therefore prevent the whole cascade.
WHY CONTINUE BREASTFEEDING?
A point that surprises students: mothers with lactational mastitis or even an abscess are generally encouraged to continue breastfeeding or expressing from the affected side. This is because the underlying driver is milk stasis — emptying the breast removes the culture medium and helps resolution — and the milk is not harmful to the infant. Stopping abruptly causes engorgement and worsens the problem.
COMPLICATIONS
Untreated or recurrent disease can lead to a chronic abscess, a mammary duct fistula (especially in the non-lactational, smoking-related periductal disease), scarring and distortion of the breast, and — the diagnosis never to miss — a mistaken label of 'abscess' on what is actually an inflammatory carcinoma, which is why non-resolving lesions are always biopsied.
A NOTE ON THE NEONATAL & ADOLESCENT BREAST
Breast infection is overwhelmingly a condition of the lactating adult, but abscesses occasionally occur in neonates (from maternal-hormone-stimulated breast tissue) and adolescents; these are managed conservatively where possible, with careful incision (avoiding the developing breast bud) if drainage is essential. In all age groups the principle is unchanged — antibiotics for cellulitis, drainage for an established collection, and biopsy for anything that does not behave as expected.
A NOTE ON RECURRENT & ATYPICAL INFECTION
Recurrent periareolar infection in a smoker points to periductal mastitis and duct ectasia, and definitive cure often requires total duct excision plus smoking cessation rather than repeated courses of antibiotics. Any breast inflammation that fails to resolve as expected — persistent erythema, an underlying mass, or skin changes — must be imaged and biopsied to exclude inflammatory carcinoma, a cancer that characteristically mimics infection with a red, swollen, peau-d'orange breast. Vigilance for this mimic is the single most important safety point in managing 'breast infection'.
🔑KEY POINTS TO REMEMBER- Breast abscess = collection of pus, usually following unresolved mastitis; drain the pus.
- Lactational: milk stasis + cracked nipple → Staphylococcus aureus; painful red wedge-shaped area + fever; keep breastfeeding/expressing.
- Non-lactational: smoking + duct ectasia/periductal mastitis; periareolar, mixed/anaerobic organisms, recurs, may form duct fistula.
- Mastitis (no pus) → antibiotics; established abscess → ultrasound-guided aspiration (first-line) or incision and drainage.
- Biopsy the wall / image if atypical or non-resolving — exclude inflammatory carcinoma; stop smoking in non-lactational disease.
📚SOURCES: Bailey & Love's Short Practice of Surgery.THE CONCEPT — THE KEY QUESTIONS
Nipple discharge is common and usually benign, but it can occasionally signal cancer, so the assessment is a structured attempt to answer a few key questions: is it from one duct or many, one breast or both, spontaneous or only on squeezing, and what colour is it? The answers separate the reassuring physiological discharge from the discharge that needs investigation. Broadly, bilateral, multi-duct, non-spontaneous discharge is benign; unilateral, single-duct, spontaneous or blood-stained discharge is 'suspicious' and must be worked up.
PHYSIOLOGICAL & GALACTORRHOEA
Physiological discharge — small amounts of milky or greenish fluid from multiple ducts of both breasts, only on squeezing — is benign and needs only reassurance. Galactorrhoea is a copious milky discharge unrelated to lactation, caused by hyperprolactinaemia — from a pituitary prolactinoma, drugs (dopamine antagonists), or hypothyroidism — so it is investigated with a serum prolactin, thyroid function and, if raised, pituitary imaging.
PATHOLOGICAL CAUSES BY COLOUR
- Blood-stained (or serosanguinous) — the most important to investigate. The commonest cause is a benign duct papilloma, but it can also be duct ectasia or an underlying carcinoma (especially DCIS).
- Thick, cheesy, green/brown, multi-duct — typical of duct ectasia in an older woman.
- Purulent — suggests infection (abscess/periductal mastitis).
- Milky — physiological or galactorrhoea (see above).
ASSESSMENT & MANAGEMENT
A patient with suspicious (single-duct, spontaneous or bloody) discharge undergoes triple assessment — examination (looking for a lump and identifying the discharging duct), imaging (mammography ± ultrasound), and testing the discharge (for blood) with biopsy of any mass. Where no cause is found but the discharge is troublesome or suspicious, the discharging duct(s) are excised — microdochectomy (single duct, to preserve breastfeeding in the young) or total duct excision (Hadfield's procedure) (multiple ducts in the older woman) — which is both diagnostic and therapeutic.
💡CLINICAL PEARL: The discharge features that should trigger full investigation are easy to remember as they are all 'single and spontaneous': unilateral, single-duct, spontaneous, and blood-stained. A duct papilloma is the commonest cause of bloody discharge and is benign — but you cannot assume that without excluding an underlying cancer by triple assessment.THE DUCT PAPILLOMA
Since it is the commonest cause of the most worrying discharge, the intraductal papilloma deserves emphasis. It is a small, benign, wart-like epithelial growth within a large subareolar duct, and as it is friable it bleeds, producing spontaneous, unilateral, single-duct, blood-stained discharge — often with no palpable lump. It is diagnosed and treated by microdochectomy (excising the affected duct), which also provides histology to confirm it is benign and exclude a papillary carcinoma.
A STRUCTURED APPROACH
Faced with nipple discharge, a logical scheme is: first decide if it is galactorrhoea (bilateral, milky, multi-duct → check prolactin/thyroid and drugs); if not, decide whether it is benign-type (bilateral, multi-duct, on pressure, green/brown → reassure ± treat duct ectasia) or suspicious-type (unilateral, single-duct, spontaneous, bloody → full triple assessment and duct excision). This algorithm ensures the small number of sinister discharges are always investigated while the majority are reassured.
INVESTIGATIONS
Useful investigations include examination to identify the discharging duct and any lump, testing the fluid for blood, mammography and ultrasound (and, for a single discharging duct, sometimes ductography or ductoscopy), and cytology of the fluid (though a negative cytology does not exclude cancer). A discrete lesion is biopsied.
A NOTE ON MALIGNANT CAUSES
Although most nipple discharge is benign, the features that raise concern for an underlying malignancy (usually DCIS, occasionally invasive or papillary carcinoma) are a bloody or serous single-duct discharge in an older woman, an associated mass, or associated microcalcification on mammography. This is why the 'suspicious' discharge is never simply reassured: even though the commonest cause (duct papilloma) is benign, only triple assessment and, where indicated, duct excision can safely exclude cancer.
A STRUCTURED DIAGNOSTIC ALGORITHM
Faced with nipple discharge, a stepwise scheme keeps the assessment safe: first identify galactorrhoea (bilateral, milky, multi-duct → check prolactin, thyroid function, drug history); then separate clearly benign-type discharge (bilateral, multi-duct, on expression, green/brown → reassure, treat duct ectasia) from suspicious discharge (unilateral, single-duct, spontaneous, blood-stained → full triple assessment and, where needed, duct excision). This algorithm reliably investigates the small proportion of sinister discharges while reassuring the majority, and it always ends by excluding an underlying carcinoma before a benign cause is accepted.
🔑KEY POINTS TO REMEMBER- Key questions: single vs multiple ducts, unilateral vs bilateral, spontaneous vs on squeezing, and colour.
- Benign/physiological: bilateral, multi-duct, on squeezing, milky/green — reassure.
- Galactorrhoea (milky, non-lactational) = hyperprolactinaemia (prolactinoma, drugs, hypothyroidism) → prolactin, TFTs, pituitary imaging.
- Suspicious: unilateral, single-duct, spontaneous, blood-stained → triple assessment; commonest cause of bloody discharge is duct papilloma (but exclude carcinoma/DCIS).
- Treat by microdochectomy (single duct) or total duct excision/Hadfield's (multiple ducts) when needed.
📚SOURCES: Bailey & Love's Short Practice of Surgery.THE CONCEPT
A fibroadenoma is the commonest benign breast tumour and the commonest breast lump in young women (15–30 years). It is best understood not as a true neoplasm but as an aberration of normal development (ANDI) — a single breast lobule overgrows, producing a well-defined lump made of both glandular (adeno) and fibrous (fibro) tissue. Because it is hormone-responsive, it tends to grow in pregnancy and regress after menopause.
CLINICAL FEATURES
It presents as a painless, smooth, firm, rubbery, well-circumscribed lump that is remarkably mobile under the examining finger — earning the classic name 'breast mouse'. It is usually solitary and 1–3 cm. This very high mobility (because it is not fixed to surrounding tissue) is a reassuring clinical feature, though it can never substitute for formal assessment.
INVESTIGATION & MANAGEMENT
Diagnosis is confirmed by triple assessment — clinical examination, ultrasound (the imaging of choice in this young, dense-breasted age group), and core biopsy. Once confirmed as a fibroadenoma, management is often conservative — reassurance and observation — because malignant change is very rare. Excision is offered if the lump is large (> 3–4 cm), growing, symptomatic, or the patient wishes it removed, or if there is any diagnostic doubt. A 'giant' fibroadenoma (in adolescents) and the rarer phyllodes tumour (which can recur/be malignant and needs wide excision) are important variants to distinguish.
💡CLINICAL PEARL: Although a fibroadenoma is benign and highly mobile, the diagnosis is still confirmed by triple assessment rather than clinical impression — a small proportion of apparently classic lumps turn out to be a phyllodes tumour, which needs wide local excision because of its recurrence and malignant potential.VARIANTS & COURSE
Two variants matter. A giant fibroadenoma (> 5 cm, often in adolescents or during pregnancy) grows large and may need excision for size alone. The phyllodes tumour can look identical clinically but is more cellular, tends to recur and has malignant potential — so it must be distinguished on biopsy. The natural history of an ordinary fibroadenoma is benign: about a third regress, a third stay the same and a third slowly enlarge, which is why observation is reasonable once the diagnosis is secure.
EXAM POINTER
For the viva, anchor the answer on the single defining idea and its safe rule: state the mechanism, the classic clinical picture, the mandatory role of triple assessment where a lump or discharge is involved, and the specific management — and be ready to contrast the condition with the malignancy it can mimic, since that contrast is what examiners most often probe.
MANAGEMENT & COUNSELLING
Once triple assessment confirms a fibroadenoma, management is a shared decision. Many women, reassured that it is benign with negligible malignant potential, opt for observation; others prefer excision for peace of mind or if the lump is large, growing or symptomatic. Excision options include conventional surgery or, for suitable lesions, vacuum-assisted excision. The clinician also explains the natural history — that many fibroadenomas remain stable or regress — so the choice to observe is made with confidence rather than anxiety, while any change prompts re-assessment.
🔑KEY POINTS TO REMEMBER- Commonest benign breast tumour; young women (15–30); an ANDI (overgrowth of a single lobule), hormone-responsive.
- Painless, smooth, firm, very mobile 'breast mouse'; usually solitary, 1–3 cm.
- Confirm by triple assessment (ultrasound + core biopsy in this age group).
- Conservative (reassure/observe) as malignancy is rare; excise if large/growing/symptomatic or doubt.
- Distinguish from phyllodes tumour (needs wide excision — recurrence/malignant potential).
📚SOURCES: Bailey & Love's Short Practice of Surgery.THE CONCEPT
Fibrocystic change (fibroadenosis) is an extremely common, benign condition of women in the 30–50 age group, best understood as an exaggerated, aberrant response of the breast tissue to the normal monthly hormonal cycle (ANDI). The cyclical rise and fall of oestrogen and progesterone produces exaggerated proliferation and then involution in the breast lobules and stroma, giving the characteristic symptoms that vary through the menstrual cycle.
CLINICAL FEATURES
The hallmark triad is cyclical breast pain (mastalgia), lumpiness, and nodularity, all typically worse in the days before menstruation and easing afterwards. The changes are usually bilateral and most marked in the upper outer quadrants; discrete cysts may also form. The cyclical, bilateral nature and lack of a dominant hard fixed lump are reassuring, but any discrete lump within the nodularity must still be assessed.
INVESTIGATION & MANAGEMENT
A dominant lump requires triple assessment to exclude malignancy; generalised nodularity without a discrete mass needs examination and, by age, appropriate imaging. Management is largely reassurance once cancer is excluded, since it is benign: a well-fitting supportive bra, simple analgesia (NSAIDs), and lifestyle measures. For severe, persistent cyclical mastalgia, options include topical NSAIDs and, in refractory cases, hormonal agents such as danazol or tamoxifen (used cautiously because of side-effects). Symptomatic cysts are aspirated.
REASSURANCE & FOLLOW-UP
The most therapeutic intervention in fibrocystic change is often explanation and reassurance — many women fear the lumpiness represents cancer, and understanding that it is a benign, hormone-driven, cyclical process relieves much of the distress. A breast pain chart can confirm the cyclical pattern and guide treatment. Any new, discrete or dominant lump arising within the general nodularity is treated on its own merits with triple assessment, because fibrocystic change does not protect against a coincidental cancer.
A NOTE ON CANCER RISK
Most fibrocystic change carries no increased cancer risk. The exception is when biopsy shows atypical hyperplasia, which does modestly raise future risk and warrants closer follow-up — a distinction made on histology, not on symptoms.
EXAM POINTER
For the viva, anchor the answer on the single defining idea and its safe rule: state the mechanism, the classic clinical picture, the mandatory role of triple assessment where a lump or discharge is involved, and the specific management — and be ready to contrast the condition with the malignancy it can mimic, since that contrast is what examiners most often probe.
MASTALGIA MANAGEMENT & CANCER RISK
Management of fibrocystic change is dominated by reassurance and simple measures — a well-fitting supportive bra, simple analgesia and a breast pain chart to demonstrate the cyclical pattern. Refractory, severe cyclical mastalgia may warrant hormonal agents (danazol, tamoxifen) used cautiously for their side-effects. Importantly, ordinary fibrocystic change carries no increased cancer risk; the exception is when biopsy reveals atypical hyperplasia, which modestly raises future risk and prompts closer surveillance — a distinction made on histology, not symptoms.
🔑KEY POINTS TO REMEMBER- Benign, very common; women 30–50; an ANDI — exaggerated response to the cyclical hormonal changes.
- Triad: cyclical mastalgia + lumpiness + nodularity, worse premenstrually, usually bilateral; cysts may form.
- Assess any discrete lump by triple assessment to exclude cancer.
- Manage by reassurance, supportive bra, NSAIDs; severe mastalgia → danazol/tamoxifen (cautiously); aspirate symptomatic cysts.
📚SOURCES: Bailey & Love's Short Practice of Surgery.THE CONCEPT
Paget's disease of the nipple is an eczema-like change of the nipple that is actually a manifestation of an underlying breast cancer. This is the crucial idea: although it looks like a simple skin rash, it is caused by malignant ductal cells (Paget cells) migrating along the ducts to reach and infiltrate the epidermis of the nipple. Almost all cases have an underlying carcinoma — either DCIS or an invasive cancer — so Paget's disease is never treated as a skin problem alone.
CLINICAL FEATURES & THE KEY DISTINCTION
It presents as a persistent, red, scaly, itchy or weeping, eczema-like lesion that begins on the nipple and spreads to the areola, sometimes with ulceration or nipple destruction. The high-yield distinction from simple nipple eczema is anatomical: Paget's disease starts on the nipple and spreads to the areola, whereas eczema starts on the areola and spares the nipple. Any unilateral, persistent nipple lesion that fails to respond to topical treatment must raise suspicion.
INVESTIGATION & MANAGEMENT
A nipple (punch) biopsy confirms the diagnosis by showing Paget cells, and full triple assessment (including mammography) searches for the underlying tumour, which may be non-palpable. Treatment is that of the underlying cancer — usually surgery (mastectomy, or breast-conserving surgery removing the nipple-areolar complex) with radiotherapy, plus axillary staging and adjuvant therapy as dictated by the tumour.
💡CLINICAL PEARL: The rule to remember: a persistent, unilateral, eczema-like nipple lesion that involves the nipple itself is Paget's disease (cancer) until proven otherwise — treating it as eczema and simply prescribing steroid cream delays a cancer diagnosis. Eczema spares the nipple and is usually bilateral; Paget's starts at the nipple.WHY IT MATTERS CLINICALLY
Paget's disease is important precisely because it is easy to dismiss. A busy clinician may treat a red, scaly nipple as dermatitis with steroid cream; the lesion may even partially improve, giving false reassurance, while the underlying cancer progresses. The safeguard is a firm rule: any unilateral, persistent nipple lesion that does not resolve promptly with simple treatment is biopsied. Around half of patients also have a palpable underlying mass, which usually indicates an invasive cancer and a correspondingly more guarded prognosis.
EXAM POINTER
For the viva, anchor the answer on the single defining idea and its safe rule: state the mechanism, the classic clinical picture, the mandatory role of triple assessment where a lump or discharge is involved, and the specific management — and be ready to contrast the condition with the malignancy it can mimic, since that contrast is what examiners most often probe.
MANAGEMENT & PROGNOSTIC IMPLICATION
Because Paget's disease signifies an underlying cancer, treatment is that of the tumour — surgery (mastectomy, or breast-conserving surgery that removes the nipple-areolar complex) with radiotherapy, plus axillary staging and adjuvant therapy as dictated by the invasive component. The presence of a palpable mass (in about half of cases) usually indicates an invasive cancer with a correspondingly more guarded prognosis, whereas Paget's disease with only DCIS behind it does very well. The prognosis therefore depends on what lies beneath the nipple change, not on the skin lesion itself.
🔑KEY POINTS TO REMEMBER- Paget's disease = eczema-like nipple change that signifies an underlying breast carcinoma (DCIS or invasive).
- Malignant ductal (Paget) cells migrate to the nipple epidermis.
- Red, scaly, weeping lesion starting on the NIPPLE and spreading to areola; eczema does the opposite (areola, spares nipple, bilateral).
- Confirm by nipple biopsy + full triple assessment for the underlying tumour.
- Treat the underlying cancer (surgery ± radiotherapy, axillary staging); never manage as simple eczema.
📚SOURCES: Bailey & Love's Short Practice of Surgery.THE CONCEPT
Gynaecomastia is the benign enlargement of the male breast due to proliferation of glandular (ductal) tissue. The unifying mechanism is an imbalance between oestrogen and androgen activity — either too much oestrogen effect or too little androgen effect — because the breast tissue is the same in both sexes and responds to oestrogen. This is distinct from pseudogynaecomastia, which is simply fatty enlargement (in obesity) without true glandular tissue, and is distinguished by palpating a firm disc of tissue behind the nipple in true gynaecomastia.
CAUSES
It is helpful to group the causes by mechanism. Physiological gynaecomastia is common and benign at three ages — the newborn (maternal oestrogens), puberty (a transient hormonal surge), and old age (falling testosterone). Pathological causes include liver disease (reduced oestrogen breakdown), drugs (spironolactone, digoxin, cimetidine, anti-androgens, cannabis, anabolic steroids), hypogonadism and Klinefelter's syndrome, hyperthyroidism, and oestrogen-secreting tumours (testicular, adrenal).
ASSESSMENT & MANAGEMENT
Assessment aims to exclude male breast cancer (which is typically a hard, eccentric, fixed lump — unlike the soft, central, concentric disc of gynaecomastia) and to identify a treatable cause: history (drugs, symptoms), examination (including testes), and investigations (liver, thyroid, and hormone profile) as indicated. Management is to treat the cause — stop the offending drug, manage the underlying disease — since much gynaecomastia then resolves. Persistent, longstanding (fibrotic) or cosmetically distressing cases may need surgical excision (subcutaneous mastectomy) or liposuction.
ASSESSMENT IN PRACTICE
A practical assessment starts by distinguishing true gynaecomastia (a firm, mobile, concentric disc of tissue felt behind the areola) from pseudogynaecomastia (soft fat, no disc) and from male breast cancer (a hard, painless, eccentric, often fixed lump, perhaps with skin or nipple change). Any features suggesting cancer, or a unilateral firm eccentric mass, prompt triple assessment. Otherwise, targeted tests — drug history, liver and thyroid function, and a hormone profile (testosterone, LH, oestrogen, prolactin, hCG) — look for a treatable cause, especially in new, tender or progressive cases.
EXAM POINTER
For the viva, anchor the answer on the single defining idea and its safe rule: state the mechanism, the classic clinical picture, the mandatory role of triple assessment where a lump or discharge is involved, and the specific management — and be ready to contrast the condition with the malignancy it can mimic, since that contrast is what examiners most often probe.
MALE BREAST CANCER — THE KEY EXCLUSION
The single most important task in assessing gynaecomastia is to exclude male breast cancer, which, though rare, presents as a hard, painless, eccentric (off-centre) fixed lump, sometimes with skin dimpling or nipple change or discharge — quite unlike the soft, central, concentric, often tender disc of true gynaecomastia. Any such suspicious features trigger triple assessment. Reassuringly, most gynaecomastia is benign and physiological or drug-related, and resolves when the cause is removed; surgery is reserved for persistent, fibrotic or cosmetically distressing cases.
🔑KEY POINTS TO REMEMBER- Gynaecomastia = benign enlargement of male breast glandular tissue from an oestrogen:androgen imbalance (vs pseudogynaecomastia = fat only).
- Physiological (benign): newborn, puberty, old age.
- Pathological: liver disease, drugs (spironolactone, digoxin, cimetidine, anti-androgens), hypogonadism/Klinefelter's, hyperthyroidism, oestrogen-secreting tumours.
- Exclude male breast cancer (hard, eccentric, fixed) and find a treatable cause.
- Treat the cause; excision/liposuction for persistent or distressing cases.
📚SOURCES: Bailey & Love's Short Practice of Surgery.THE CONCEPT & EVOLUTION
A modified radical mastectomy (MRM) is the removal of the entire breast together with the axillary lymph nodes, while preserving the pectoralis major (and usually pectoralis minor) muscles. Its history teaches the principle: the older Halsted radical mastectomy also removed both pectoral muscles, causing great deformity and disability for no survival benefit. The MRM was the realisation that removing the muscles was unnecessary, giving equivalent cancer control with far less morbidity — which is why it replaced the radical operation.
WHAT IS REMOVED & INDICATIONS
The MRM removes the whole breast, the nipple-areolar complex, the skin overlying the tumour, and the axillary lymph nodes (levels I–II, sometimes III), preserving the pectoral muscles. It is indicated for breast cancer unsuitable for breast-conserving surgery — a large tumour relative to breast size, multifocal/multicentric disease, extensive DCIS, inflammatory cancer (after chemotherapy), contraindication to radiotherapy, or patient preference — usually with a proven axilla requiring clearance.
COMPLICATIONS
Knowing the anatomy predicts the complications: general ones (haematoma, seroma — very common, wound infection, flap necrosis); and specific ones from the axillary dissection — lymphoedema of the arm, damage to the long thoracic nerve (winged scapula), the thoracodorsal nerve, or the intercostobrachial nerve (numbness of the inner arm), and shoulder stiffness. Breast reconstruction (immediate or delayed) is offered to restore body image.
POST-OPERATIVE CARE & RECONSTRUCTION
After an MRM a suction drain is left to reduce seroma, and early shoulder physiotherapy prevents a frozen shoulder. Long-term, patients are counselled on lymphoedema prevention (avoiding venepuncture, blood-pressure cuffs and injury to the arm on the operated side). Breast reconstruction — using an implant or the patient's own tissue (e.g. a latissimus dorsi or DIEP flap) — can be performed immediately or later, and is an important part of restoring quality of life and body image after mastectomy.
EXAM POINTER
For the viva, anchor the answer on the single defining idea and its safe rule: state the mechanism, the classic clinical picture, the mandatory role of triple assessment where a lump or discharge is involved, and the specific management — and be ready to contrast the condition with the malignancy it can mimic, since that contrast is what examiners most often probe.
OPERATIVE DETAIL & LYMPHOEDEMA
The morbidity of the MRM comes mainly from the axillary dissection, so modern practice stages the axilla with a sentinel node biopsy and reserves full clearance for proven nodal disease, reducing the risk of lymphoedema. Where clearance is done, patients are counselled on lifelong lymphoedema-prevention measures (avoiding venepuncture, blood-pressure cuffs and injury to the arm on the operated side) and offered early physiotherapy for shoulder movement. Reconstruction is discussed as part of the same operative plan, immediate or delayed, to restore form and function.
🔑KEY POINTS TO REMEMBER- MRM = removal of whole breast + axillary nodes, PRESERVING pectoralis major/minor.
- Replaced the Halsted radical mastectomy (which removed the pectoral muscles) — same control, much less morbidity.
- Removes breast, nipple-areolar complex, overlying skin, axillary nodes (levels I–II ± III).
- Indicated when breast conservation is unsuitable (large/multifocal tumour, extensive DCIS, inflammatory cancer, radiotherapy contraindicated, patient choice).
- Complications: seroma, lymphoedema, nerve injuries (long thoracic → winged scapula, thoracodorsal, intercostobrachial); offer reconstruction.
📚SOURCES: Bailey & Love's Short Practice of Surgery; SRB's Manual of Surgery.THE CONCEPT
Mammary duct ectasia ('ectasia' = dilatation) is a benign condition of peri- and post-menopausal women in which the large subareolar ducts dilate, shorten and fill with stagnant secretions. The retained secretions irritate the duct wall and can leak into surrounding tissue, provoking a chronic inflammatory reaction (periductal mastitis). Its importance is that it is a benign condition that closely mimics breast cancer, which is the main reason it is examined and must be worked up carefully.
CLINICAL FEATURES
It produces a cluster of features that individually can suggest malignancy: a thick, cheesy, often green or brown nipple discharge (typically from multiple ducts); nipple retraction/inversion (as the shortening ducts pull the nipple in — a slit-like retraction); a subareolar mass or thickening; and sometimes periareolar inflammation, abscess or a mammary duct fistula. It is strongly associated with smoking.
INVESTIGATION & MANAGEMENT
Because the picture overlaps with carcinoma (retraction, mass, discharge), triple assessment is mandatory to exclude malignancy — mammography may show characteristic dilated ducts and benign 'tram-track' calcification. Once cancer is excluded, most cases need only reassurance and smoking cessation. Troublesome discharge, recurrent infection or a fistula is treated by total duct excision (Hadfield's operation), which removes the diseased subareolar ducts.
💡CLINICAL PEARL: Duct ectasia is the classic benign mimic of breast cancer — it can produce nipple retraction, a subareolar lump and discharge all at once. The safe approach is never to diagnose it clinically: exclude carcinoma with triple assessment first, then reassure.PERIDUCTAL MASTITIS & THE FISTULA
Duct ectasia is closely linked to periductal mastitis (inflammation around the ducts), and in smokers this can lead to recurrent periareolar abscesses and a mammary duct fistula — an abnormal track between a subareolar duct and the skin at the areolar margin, which discharges and recurs until the diseased duct is excised. Recognising this smoking-associated pattern, and advising smoking cessation, is central to breaking the cycle of recurrent infection.
EXAM POINTER
For the viva, anchor the answer on the single defining idea and its safe rule: state the mechanism, the classic clinical picture, the mandatory role of triple assessment where a lump or discharge is involved, and the specific management — and be ready to contrast the condition with the malignancy it can mimic, since that contrast is what examiners most often probe.
MANAGEMENT & THE MIMIC OF CANCER
Because duct ectasia can reproduce almost every sign of breast cancer — nipple retraction, a subareolar mass, and discharge — the cardinal rule is that it is a diagnosis of exclusion made only after triple assessment has ruled out malignancy. Once cancer is excluded, most patients need only reassurance and smoking cessation; troublesome discharge, recurrent periareolar sepsis, or a mammary duct fistula is treated by total duct excision (Hadfield's operation). This 'exclude cancer, then reassure' sequence is the safe approach to every feature duct ectasia can mimic.
🔑KEY POINTS TO REMEMBER- Duct ectasia = dilated, shortened subareolar ducts filled with stagnant secretions (peri/postmenopausal); can cause periductal mastitis.
- Mimics cancer: thick cheesy green/brown multi-duct discharge, slit-like nipple retraction, subareolar mass, ± abscess/duct fistula; linked to smoking.
- Triple assessment is mandatory to exclude carcinoma.
- Manage by reassurance + smoking cessation; total duct excision (Hadfield's) for troublesome discharge/recurrent infection/fistula.
📚SOURCES: Bailey & Love's Short Practice of Surgery.THE CONCEPT
A phyllodes tumour (cystosarcoma phyllodes) is a fibroepithelial tumour of the breast that, like a fibroadenoma, contains both stromal and epithelial elements — but with a much more cellular, overgrown stroma. The name 'phyllodes' (Greek for 'leaf-like') describes the leaf-like clefts seen on cut section and histology. Its significance is that, unlike the harmless fibroadenoma it resembles, it has a tendency to recur locally and a spectrum of malignant potential, so it is managed quite differently.
CLINICAL FEATURES
It typically occurs in women older than those with fibroadenoma (around 40–50) and presents as a firm, mobile, often large and rapidly growing breast lump. The history of a smooth mobile lump that has grown quickly to a large size, sometimes stretching and shining the overlying skin, is characteristic and helps distinguish it clinically from a stable fibroadenoma.
CLASSIFICATION & MANAGEMENT
On histology, phyllodes tumours are graded benign, borderline or malignant according to stromal features (cellularity, mitoses, margins, overgrowth). Because even benign ones recur if incompletely removed, the treatment is wide local excision with a clear margin (about 1 cm) — not simple enucleation as for a fibroadenoma; large tumours may require mastectomy. The malignant variant spreads haematogenously (like a sarcoma, e.g. to the lung) rather than to lymph nodes, so axillary clearance is not routinely required.
DISTINGUISHING IT FROM FIBROADENOMA
The clinically vital comparison is with the fibroadenoma it mimics. Points favouring a phyllodes tumour are an older patient, a larger size, and rapid recent growth of a previously stable or new lump. The distinction genuinely matters because the operations differ: a fibroadenoma can be simply enucleated or observed, whereas a phyllodes tumour requires wide excision with a clear margin to prevent local recurrence — so mislabelling a phyllodes tumour as a fibroadenoma and 'shelling it out' leads to recurrence.
EXAM POINTER
For the viva, anchor the answer on the single defining idea and its safe rule: state the mechanism, the classic clinical picture, the mandatory role of triple assessment where a lump or discharge is involved, and the specific management — and be ready to contrast the condition with the malignancy it can mimic, since that contrast is what examiners most often probe.
MANAGEMENT & FOLLOW-UP
Because a phyllodes tumour recurs if incompletely excised, treatment is wide local excision with a clear margin of about 1 cm (mastectomy for very large tumours), and — unlike breast carcinoma — axillary clearance is not routine, since the malignant variant spreads haematogenously (to the lung) rather than to nodes. Patients are followed for local recurrence, which even benign phyllodes tumours can show. The recurring exam theme is the contrast with fibroadenoma: an older patient, a larger and rapidly growing lump, and an operation demanding a proper margin rather than simple enucleation.
🔑KEY POINTS TO REMEMBER- Phyllodes tumour = fibroepithelial tumour with a hypercellular, overgrown stroma; leaf-like clefts.
- Older than fibroadenoma patients (~40–50); firm, mobile, often large, rapidly growing lump.
- Graded benign / borderline / malignant; tends to recur locally.
- Treat by wide local excision with ~1 cm clear margin (not enucleation); mastectomy for large tumours.
- Malignant type spreads haematogenously (lung), not to nodes — no routine axillary clearance.
📚SOURCES: Bailey & Love's Short Practice of Surgery; SRB's Manual of Surgery.